FTC requires BMS-Celgene to divest psoriasis drug Otezla to get antitrust approval
MLex Summary: Bristol-Myers Squibb and Celgene have agreed to divest Celgene’s psoriasis drug, Otezla, for $13.4 billion to settle Federal Trade Commission charges that the companies' merger would violate US antitrust laws. “The...To view the full article, register now.
Already a subscriber? Click here to view full article